← Back to Search

Monoclonal Antibodies

ADCT-701 for Rare Cancers

Q: Are individuals of at least 25 years old being welcomed into the research?

The requirements for this research dictate that patients must be between 18 and 120 years old. For those under the age of 18, there are 97 separate projects to explore. Alternatively, 2711 studies exist that cater towards elderly participants.

Q: To what degree does 1/Arm1 present a risk to human health?

Our assessment of Arm1's safety is a 1, which reflects the limited data available from this Phase 1 trial that investigates both efficacy and danger.

Q: What qualifications are necessary to take part in this medical investigation?

This clinical trial seeks 70 individuals with neuroendocrine carcinoma aged 18-120 to participate. Most significantly, qualified candidates must have undergone either radiation therapy of surgery at least four weeks prior and show no signs of progression or associated symptoms.

Q: Are there still vacancies for participants in this clinical experiment?

This medical trial, initially posted on September 28th 2023 and updated most recently on the 22nd of that same month, is not currently registering patients. However, 2736 other studies are actively enrolling individuals at this time.

Phase 1

Recruiting

Led By Jaydira Del Rivero, M.D.

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status <= 2

Breastfeeding participants must be willing to discontinue breastfeeding

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial tests a new drug for adults with rare cancers in the digestive system, pancreas, lungs, and other parts of the body. Participants will have tests and receive the drug every 21 days for up to 2 years, with follow-up for up to 5 years.

Who is the study for?

Adults over 18 with neuroendocrine tumors or adrenocortical carcinoma, who've tried standard treatments without success. They must have measurable disease, be able to perform daily activities to a certain extent, and agree to use contraception. Excluded are those with recent other cancer treatments, uncontrolled illnesses, certain heart conditions, active infections or allergies related to the study drug.Check my eligibility

What is being tested?

The trial is testing ADCT-701 in patients with rare cancers of various glands. It involves receiving the drug through an IV on day one of each 21-day cycle for up to two years. Participants will undergo regular clinic visits that include physical exams and various tests like imaging scans and blood draws.See study design

What are the potential side effects?

Specific side effects of ADCT-701 aren't listed but may include typical reactions from similar cancer drugs such as fatigue, nausea, allergic reactions, blood count changes leading to increased infection risk or bleeding tendencies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself but might not be able to do heavy physical work.

Select...

I am breastfeeding but willing to stop for the trial.

Select...

I have been diagnosed with a neuroendocrine tumor or adrenal cancer.

Select...

I am 18 years old or older.

Select...

My cancer has spread beyond its original location.

Select...

I've tried and didn't respond or couldn't tolerate the usual treatments.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determine the maximum tolerated dose (MTD) of ADCT-701

Secondary outcome measures

Immunogenicity of ADCT-701

PK profile of ADCT-701

Preliminary anti-tumor activity of ADCT-701

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: 1/Arm1Experimental Treatment1 Intervention

ADCT-701 given as an IV infusion

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor

13,672 Previous Clinical Trials

40,926,371 Total Patients Enrolled

Jaydira Del Rivero, M.D.Principal InvestigatorNational Cancer Institute (NCI)

4 Previous Clinical Trials

1,345 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals of at least 25 years old being welcomed into the research?

"The requirements for this research dictate that patients must be between 18 and 120 years old. For those under the age of 18, there are 97 separate projects to explore. Alternatively, 2711 studies exist that cater towards elderly participants."

Answered by AI

To what degree does 1/Arm1 present a risk to human health?

"Our assessment of Arm1's safety is a 1, which reflects the limited data available from this Phase 1 trial that investigates both efficacy and danger."

Answered by AI

What qualifications are necessary to take part in this medical investigation?

"This clinical trial seeks 70 individuals with neuroendocrine carcinoma aged 18-120 to participate. Most significantly, qualified candidates must have undergone either radiation therapy of surgery at least four weeks prior and show no signs of progression or associated symptoms."

Answered by AI

Are there still vacancies for participants in this clinical experiment?

"This medical trial, initially posted on September 28th 2023 and updated most recently on the 22nd of that same month, is not currently registering patients. However, 2736 other studies are actively enrolling individuals at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

2024. "Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06041516.

All > Neuroendocrine Tumor